The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,933,320 in first-year total cost, median $532,820.
Most frequent study sections
- Special Emphasis Panel[ZAI1 BDP-I (M4)]1
- Special Emphasis Panel[ZAI1 BP-A (J1)]1
- Special Emphasis Panel[ZAI1 QV-I (M1)]1
Most frequent institutions
- AURITEC PHARMACEUTICALS, INC.1
- GENERAL INNOVATIONS AND GOODS, INC.1
- SYNTRIX BIOSYSTEMS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2016 | Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus2U44AI069674-04A1 | SMITH, THOMAS J. | AURITEC PHARMACEUTICALS, INC., CA | $532,820 | ZAI1 |
| 2014 | Health Effects of CREON2000 in Asthmatic Children2U44AI074918-02 | BERNSTEIN, JONATHAN ABRAMGLAZMAN, MARK | GENERAL INNOVATIONS AND GOODS, INC., OH | $1,175,500 | ZAI1 |
| 2014 | Efficacy and resistance mechanisms of LD-aminopterin in psoriasis1U44AI114473-01 | KAHN, STUART JZEBALA, JOHN A | SYNTRIX BIOSYSTEMS, INC., WA | $225,000 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.